| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Panobinostat | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.0097 | 0.8 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | -0.05 | 0.8 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.017 | 0.8 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |